2025年6月,复星国际(00656.HK)生物创新药平台——复宏汉霖自主研发的抗PD-1单抗H药汉斯状获英国药品和保健品监管局、印度中央药品标准控制组织批准,用于广泛期小细胞肺癌(ES-SCLC)的一线治疗;当月汉斯状还获得新加坡卫生科学局和马来西亚国家药品监管局批准,用于治疗ES-SCLC。肺癌是全球发病率和死亡率最高的恶性肿瘤,小细胞肺癌是肺癌中侵袭性最强的亚型,约占肺癌总数的15%,据统计...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.